TATVA CHIN PHARM CHEM Latest Share Price (TATVA)
TODAY IN ONE LINE
TATVA slipped 0.8% on average volume, lagging Nifty's 1.1% move, supported by recent strong earnings.
With a market cap of ₹3,787.17 Cr., it trades at a P/E of 60.19. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
TATVA CHIN PHARM CHEM flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 907.5% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 30.1% and Profit up 34.2%
- ●High Promoter HoldingPromoters hold 72.0% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.15x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Capital ReturnsLow ROE of 5.4%
- ●Expensive ValuationTrading at a high P/E ratio of 66.2x
- ●Rising Receivables vs SalesReceivables grew 23.2% outpacing sales growth of -2.7%
Latest TATVA CHIN PHARM CHEM News
What changed recently?
Recent events, corporate actions, and announcements.
TATVA CHIN PHARM CHEM valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for TATVA CHIN PHARM CHEM, framed against the sector median so the premium or discount is obvious at a glance.
TATVA CHIN PHARM CHEM trades at a P/E of 60.19× and P/B of 4.65×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
TATVA CHIN PHARM CHEM technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for TATVA CHIN PHARM CHEM — derived from the latest tape, not yesterday's close.
TATVA CHIN PHARM CHEM last traded at ₹1,614.8 with an intraday range of ₹1,581–₹1,637 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1614.80| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1752.87 | +138.07 | +8.55% |
| R3 | 1696.87 | +82.07 | +5.08% |
| R2 | 1666.93 | +52.13 | +3.23% |
| R1 | 1640.87 | +26.07 | +1.61% |
| PIVOT | 1610.93 | -3.87 | -0.24% |
| CURRENT | 1614.80 | — | — |
| S1 | 1584.87 | -29.93 | -1.85% |
| S2 | 1554.93 | -59.87 | -3.71% |
| S3 | 1528.87 | -85.93 | -5.32% |
| S4 | 1472.87 | -141.93 | -8.79% |
TATVA is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹1600.2–₹1637
Trading Inside opening range
TATVA CHIN PHARM CHEM financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for TATVA CHIN PHARM CHEM — consolidated or standalone — with margins, YoY growth and key ratios inline.
TATVA CHIN PHARM CHEM reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹3,787.17 Cr. and reported EPS of ₹9.17.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 506 | 506 ▲ 0.0% |
| Sales Growth YoY %Derived | 32.18% | 32.18% |
| Other Income | 4 | 4 ▲ 0.0% |
| Total Income | 509 | 509 ▲ 0.0% |
| 225 | 225 ▲ 0.0% | |
| Gross ProfitDerived | 281 | 281 ▲ 0.0% |
| Gross Margin %Derived | 55.61% | 55.61% |
| 188 | 188 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 93 | 93 ▲ 0.0% |
| OPM %Derived | 18.42% | 18.42% |
| 40 | 40 ▲ 0.0% | |
| Profit Before Tax (PBT) | 57 | 57 ▲ 0.0% |
| 15 | 15 ▲ 0.0% | |
| Effective Tax %Derived | 26.23% | 26.23% |
| Total Profit for Period | 42 | 42 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | 42 | 42 ▲ 0.0% |
| Net Profit Margin %Derived | 8.31% | 8.31% |
| PAT Growth YoY %Derived | 636.11% | 636.11% |
| Earnings Per Share (EPS ₹) | 17.98 | 17.98 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 3 | 3 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 452 | 452 ▲ 0.0% |
| Material Cost % of RevenueDerived | 51.94% | 51.94% |
| Employee Cost % of RevenueDerived | 12.44% | 12.44% |
| Other Cost % of RevenueDerived | 24.76% | 24.76% |
| Interest Coverage (x)Derived | 19.75x | 19.75x |
| Period | Mar 2022 | Apr 2022 | Mar 2023 | May 2023 | Mar 2024 | May 2024 | Mar 2025 | May 2025 | Mar 2026 | May 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 434 | 434 ▲ 0.0% | 424 ▼ 2.3% | 424 ▲ 0.0% | 394 ▼ 7.1% | 394 ▲ 0.0% | 383 ▼ 2.7% | 383 ▲ 0.0% | 506 ▲ 32.2% | 506 ▲ 0.0% | |
| Sales Growth YoY %Derived | — | — | -2.31% | — | -7.11% | -7.11% | -2.74% | -2.74% | 32.18% | 32.18% | |
| Other Income | 9 | 9 ▲ 0.0% | 6 ▼ 35.4% | 6 ▲ 0.0% | 8 ▲ 30.7% | 8 ▲ 0.0% | 2 ▼ 69.2% | 2 ▲ 0.0% | 4 ▲ 53.3% | 4 ▲ 0.0% | |
| Total Income | 443 | 443 ▲ 0.0% | 429 ▼ 3.0% | 429 ▲ 0.0% | 401 ▼ 6.6% | 401 ▲ 0.0% | 385 ▼ 4.0% | 385 ▲ 0.0% | 509 ▲ 32.3% | 509 ▲ 0.0% | |
195 | 195 ▲ 0.0% | 226 ▲ 16.2% | 226 ▲ 0.0% | 174 ▼ 23.0% | 174 ▲ 0.0% | 199 ▲ 14.2% | 199 ▲ 0.0% | 225 ▲ 12.9% | 225 ▲ 0.0% | ||
| Gross ProfitDerived | 239 | 239 ▲ 0.0% | 198 ▼ 17.4% | 198 ▲ 0.0% | 219 ▲ 11.0% | 219 ▲ 0.0% | 184 ▼ 16.2% | 184 ▲ 0.0% | 281 ▲ 53.1% | 281 ▲ 0.0% | |
| Gross Margin %Derived | 55.12% | 55.12% | 46.63% | 46.63% | 55.74% | 55.74% | 48.02% | 48.02% | 55.61% | 55.61% | |
131 | 131 ▲ 0.0% | 137 ▲ 4.7% | 137 ▲ 0.0% | 151 ▲ 10.4% | 151 ▲ 0.0% | 150 ▼ 1.0% | 150 ▲ 0.0% | 188 ▲ 25.8% | 188 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 108 | 108 ▲ 0.0% | 61 ▼ 44.0% | 61 ▲ 0.0% | 68 ▲ 12.6% | 68 ▲ 0.0% | 34 ▼ 49.8% | 34 ▲ 0.0% | 93 ▲ 172.3% | 93 ▲ 0.0% | |
| OPM %Derived | 24.96% | 24.96% | 14.30% | 14.30% | 17.33% | 17.33% | 8.94% | 8.94% | 18.42% | 18.42% | |
13 | 13 ▲ 0.0% | 14 ▲ 10.5% | 14 ▲ 0.0% | 32 ▲ 123.6% | 32 ▲ 0.0% | 29 ▼ 9.9% | 29 ▲ 0.0% | 40 ▲ 37.1% | 40 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 104 | 104 ▲ 0.0% | 45 ▼ 57.0% | 45 ▲ 0.0% | 44 ▼ 2.7% | 44 ▲ 0.0% | 8 ▼ 82.6% | 8 ▲ 0.0% | 57 ▲ 652.2% | 57 ▲ 0.0% | |
8 | 8 ▲ 0.0% | -1 ▼ 108.6% | -1 ▲ 0.0% | 13 ▲ 1966.4% | 13 ▲ 0.0% | 2 ▼ 85.9% | 2 ▲ 0.0% | 15 ▲ 701.4% | 15 ▲ 0.0% | ||
| Effective Tax %Derived | 7.92% | 7.92% | -1.58% | -1.58% | 30.33% | 30.33% | 24.62% | 24.62% | 26.23% | 26.23% | |
| Total Profit for Period | 96 | 96 ▲ 0.0% | 45 ▼ 52.6% | 45 ▲ 0.0% | 30 ▼ 33.3% | 30 ▲ 0.0% | 6 ▼ 81.2% | 6 ▲ 0.0% | 42 ▲ 636.1% | 42 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 96 | 96 ▲ 0.0% | 45 ▼ 52.6% | 45 ▲ 0.0% | 30 ▼ 33.3% | 30 ▲ 0.0% | 6 ▼ 81.2% | 6 ▲ 0.0% | 42 ▲ 636.1% | 42 ▲ 0.0% | |
| Net Profit Margin %Derived | 22.11% | 22.11% | 10.74% | 10.74% | 7.71% | 7.71% | 1.49% | 1.49% | 8.31% | 8.31% | |
| PAT Growth YoY %Derived | — | — | -52.56% | — | -33.27% | -33.27% | -81.18% | -81.18% | 636.11% | 636.11% | |
| Earnings Per Share (EPS ₹) | 43.25 | 43.25 ▲ 0.0% | 20.52 ▼ 52.6% | 20.52 ▲ 0.0% | 12.98 ▼ 36.7% | 12.98 ▲ 0.0% | 2.44 ▼ 81.2% | 2.44 ▲ 0.0% | 17.98 ▲ 636.9% | 17.98 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.0% | 2 ▲ 0.0% | 2 ▲ 0.0% | 2 ▲ 5.5% | 2 ▲ 0.0% | 2 ▲ 0.0% | 2 ▲ 0.0% | 2 ▲ 0.0% | 2 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▲ 0.0% | 1 ▲ 546.9% | 1 ▲ 0.0% | 0 ▼ 96.8% | 0 ▲ 0.0% | 1 ▲ 3266.7% | 1 ▲ 0.0% | 3 ▲ 355.4% | 3 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 338 | 338 ▲ 0.0% | 385 ▲ 13.6% | 385 ▲ 0.0% | 357 ▼ 7.1% | 357 ▲ 0.0% | 377 ▲ 5.6% | 377 ▲ 0.0% | 452 ▲ 19.9% | 452 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 58.69% | 58.69% | 50.95% | 50.95% | 45.43% | 45.43% | 45.40% | 45.40% | 51.94% | 51.94% | |
| Employee Cost % of RevenueDerived | 7.11% | 7.11% | 9.11% | 9.11% | 13.92% | 13.92% | 13.83% | 13.83% | 12.44% | 12.44% | |
| Other Cost % of RevenueDerived | 23.05% | 23.05% | 23.21% | 23.21% | 24.49% | 24.49% | 25.25% | 25.25% | 24.76% | 24.76% | |
| Interest Coverage (x)Derived | 20.71x | 20.71x | 6.07x | 6.07x | 6.52x | 6.52x | 5.08x | 5.08x | 19.75x | 19.75x |
TATVA CHIN PHARM CHEM segment analysis : revenue and profit mix.
Disclosed business segments at TATVA CHIN PHARM CHEM with their share of revenue and profit, switchable between consolidated and standalone reporting.
TATVA CHIN PHARM CHEM discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for TATVA CHIN PHARM CHEM.
Our AI distills the core fundamental drivers supporting TATVA CHIN PHARM CHEM, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Valuation risk. a P/E above 78 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
TATVA CHIN PHARM CHEM peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — TATVA CHIN PHARM CHEM is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
TATVA CHIN PHARM CHEM chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for TATVA CHIN PHARM CHEM — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
TATVA CHIN PHARM CHEM delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for TATVA CHIN PHARM CHEM over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in TATVA CHIN PHARM CHEM stood at 42.3% of traded volume, against a 20-day average of 39.7%.
TATVA CHIN PHARM CHEM announcements: results, concalls, ratings, M&A.
Filings TATVA CHIN PHARM CHEM sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
TATVA CHIN PHARM CHEM files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 158 documents below.
Copy of Newspaper Publication
Tatva Chintan Pharma Chem Limited has informed the Exchange about Copy of Newspaper Publication
General Updates
Tatva Chintan Pharma Chem Limited has informed the Exchange about Updated Investor Presentation.
Investor Presentation
Tatva Chintan Pharma Chem Limited has informed the Exchange about Investor Presentation
Updates
Tatva Chintan Pharma Chem Limited has informed the Exchange regarding 'Earnings call scheduled to be held on Monday, 19 October 2026 at 05:00 p.m.…
Outcome of Board Meeting
Tatva Chintan Pharma Chem Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Investor decks & rating reports.
TATVA CHIN PHARM CHEM dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue TATVA CHIN PHARM CHEM has declared, sequenced by announce and record date.
TATVA CHIN PHARM CHEM corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About TATVA CHIN PHARM CHEM: business, sector, key facts.
What TATVA CHIN PHARM CHEM does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
TATVA CHIN PHARM CHEM operates in the Specialty Chemicals industry under the Chemicals sector, listed as NSE: TATVA, BSE: 543321.
Tatva Chintan Pharma Chem Limited (TCPL) is a prominent Indian manufacturer and supplier of specialty chemicals, catering to both domestic and international markets. Their business model centers on providing high-quality, specialized chemical compounds for a diverse range of industrial applications. This specialization distinguishes them within the broader chemical industry, allowing them to focus on niche markets and develop strong expertise in their chosen areas.
A core component of TCPL's product portfolio lies in structure-directing agents (SDAs) used in the synthesis of zeolites. Zeolites are crystalline aluminosilicate minerals with various industrial applications, and TCPL's SDAs play a crucial role in controlling the structure and properties of these materials. This demonstrates their involvement in a technologically advanced segment of the chemical industry requiring sophisticated chemical engineering and synthesis expertise.
Beyond zeolite synthesis, TCPL produces and distributes a wide array of other specialty chemicals. This includes phase-transfer catalysts, which accelerate chemical reactions; electrolyte salts for cutting-edge energy storage technologies like supercapacitors and zinc-ion batteries; and various pharmaceutical and agrochemical products. This broad product range underscores their ability to adapt to evolving market demands and serve multiple sectors.
The company's customer base spans a multitude of industries, highlighting the versatility of their chemical offerings. These include the automotive sector, refineries, pharmaceutical manufacturers, agrochemical producers, manufacturers of paints and coatings, dyes and pigments, personal care products, and companies in the flavor and fragrance industries. This widespread reach indicates the diverse applications of their specialized chemicals and their success in penetrating significant market segments.
In summary, Tatva Chintan Pharma Chem Limited operates a successful business focused on the manufacturing and sale of high-value specialty chemicals. Their expertise in specific areas, coupled with a diversified customer base and a broad product portfolio, positions them as a significant player within the global chemical industry. The company's continued focus on innovation and adaptation to emerging technological needs ensures their continued relevance and growth prospects within the market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AARTI INDUSTRIES (AARTIIND) Share PricePeer
- AARTISURF (AARTISURF) Share PricePeer
- ARCHEAN CHEMICAL IND (ACI) Share PricePeer
- AETHER INDUSTRIES (AETHER) Share PricePeer
- ALKALI (ALKALI) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about TATVA CHIN PHARM CHEM (TATVA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of TATVA CHIN PHARM CHEM (TATVA)?
The current share price of TATVA CHIN PHARM CHEM (TATVA) is ₹1,614.80. Today, the stock has declined by ₹13.00 (0.8%), trading in a range of ₹1,581.00 to ₹1,637.00. The stock opened at ₹1,637.00 with a trading volume of 46,779 shares.
02Is TATVA CHIN PHARM CHEM stock a good investment for long-term?
TATVA CHIN PHARM CHEM can be considered for long-term investment based on several factors. The company has a market capitalization of ₹3,787.17 Cr., P/E ratio of 60.19, ROE of 5.38%, and ROCE of 4.16%. The dividend yield stands at 0.12%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of TATVA CHIN PHARM CHEM stock?
The 52-week high price of TATVA CHIN PHARM CHEM (TATVA) is ₹2,113.60, while the 52-week low is ₹1,044.10. Currently trading at ₹1,614.80, the stock is 54.66% above its 52-week low and 23.6% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy TATVA CHIN PHARM CHEM stock at the current price?
Whether to buy TATVA CHIN PHARM CHEM stock at ₹1,614.80 depends on multiple factors. The stock is currently trading with a P/E ratio of 60.19 and P/B ratio of 4.65. Today's performance shows a loss of 0.8%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of TATVA CHIN PHARM CHEM and when is the next dividend?
TATVA CHIN PHARM CHEM offers a dividend yield of 0.12%, which means for every ₹100 invested at the current price of ₹1,614.80, you can expect to receive approximately ₹0.12 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of TATVA CHIN PHARM CHEM?
TATVA CHIN PHARM CHEM's key financial metrics include: P/E Ratio: 60.19, P/B Ratio: 4.65, ROE: 5.38%, ROCE: 4.16%, Dividend Yield: 0.12%, EPS: ₹9.17, Book Value: ₹334.20, and Debt-to-Equity: 0.15. The company's market cap stands at ₹3,787.17 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is TATVA CHIN PHARM CHEM stock performing today in the market?
TATVA CHIN PHARM CHEM stock opened at ₹1,637.00 and is currently trading at ₹1,614.80, showing a decline of ₹13.00 (0.8%). The intraday high is ₹1,637.00 and low is ₹1,581.00. The trading volume stands at 46,779 shares, indicating moderate market participation today.
08What is the P/E ratio of TATVA CHIN PHARM CHEM and what does it indicate?
TATVA CHIN PHARM CHEM has a Price-to-Earnings (P/E) ratio of 60.19, which means investors are willing to pay 60.19 for every ₹1 of earnings. With an EPS of ₹9.17, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about TATVA CHIN PHARM CHEM (TATVA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.